DIANTHUS THERAPEUTICS, INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 24.88 USD | -1.50% |
|
-4.31% | +139.23% |
| 06-12 | Dianthus Therapeutics Secures US FDA Approval to Launch Phase 2 Study of DNTH103 in Multifocal Motor Neuropathy | MT |
| 06-12 | Dianthus Therapeutics Gets FDA Clearance for DNTH103 Phase 2 Trial | DJ |
